Trial Profile
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Casopitant (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 27 May 2009 New trial record